Recursion

Recursion is an AI drug discovery company for pharma collaborators and internal programs, combining cellular imaging, automation, and machine learning to identify potential drug candidates.

1. Scientific approach: The platform centers on phenomics and multimodal data, supporting computational biology and R&D acceleration rather than guaranteeing clinical outcomes.
2. Engagement model: Access typically occurs through pharma partnerships instead of self-serve subscriptions, making it relevant to organizations prepared for collaborative discovery.
3. Evaluation priorities: Buyers should examine data-access requirements, timelines to validated leads, validation depth, support coverage, and program-specific costs before committing.
4. Commercial model: Pricing is sales-led and scoped per buyer rather than publicly posted, while direct buyer access remains limited to partnerships.

Its fit depends on whether Recursion’s data-rich discovery model, partnership structure, and development timelines align with the buyer’s overall program goals.